MedTrace Logo

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

NCT03530995 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2022-05-25

Study results available
· View outcomes & findings →

Summary

This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.

Conditions

Interventions

DRUG

Belumosudil

Development candidate

DRUG

Itraconazole

Perpetrator drug

DRUG

Rabeprazole

Perpetrator drug

DRUG

Rifampicin

Perpetrator drug

DRUG

Omeprazole

Perpetrator drug

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Kadmon Corporation, LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-09
Primary Completion
2019-02-08
Completion
2019-02-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03530995 on ClinicalTrials.gov